Researchers and industry leaders at the 2026 Precision Medicine World Conference argued that AI, advanced protein‑folding models, and high‑frequency personal data are enabling ‘N‑of‑1’ personalized interventions tailored to individual patients. Speakers including Vinod Khosla and Nathan Price described use cases ranging from bespoke antibodies for unique cancer mutations to individualized health‑span analyzers. A recent animal example—an AI‑assisted, ChatGPT‑designed vaccine for a dog—was cited as an early demonstration of rapid, personalized design workflows. Panelists also flagged regulatory and operational barriers: clinicians and regulators remain organized around population‑level trials, and federated data systems and safety testing will be necessary to scale individualized therapeutics. Industry leaders urged development of systematized, data‑driven pipelines and expressed uncertainty about how existing regulatory frameworks, including the FDA, will adapt to single‑patient drug approvals.